智通财经APP讯，心泰医疗(02291)发布截至2026年6月30日止6个月中期业绩，该集团取得营业总收入3.1亿元，同比减少5.94%;归属于母公司股东的净利润1.47亿元，同比减少19.49%;基本每股收益0.4226元。
本集团已搭建起先天性心脏病、电生理、瓣膜及国际贸易四个专业营销团队，持续拓展销售渠道，通过集采落地推动国内各管线产品加速市场渗透。本集团将巩固并深化与研究机构、医院、临床医生及业界专家的交流与合作，持续获取临床反馈与市场信息，优化产品设计与生产工艺，提升销售服务能力，以更好的产品及更完善的服务体系服务于医生与患者。在国内市场各管线加速渗透的同时，本集团亦同步加快海外业务的战略布局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.